Abvc Biopharma (ABVC) EBIT Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly EBIT Margin came in at 246.79% in Q3 2025, down 16913.0% on a YoY basis from N/an in Q3 2024, and up 99.31% quarter-over-quarter from 35837.44% in Q4 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) EBIT Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has reported EBIT Margin for 13 consecutive years, with 246.79% the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, EBIT Margin fell 16913.0% year-over-year to 246.79%; the trailing twelve-month figure through Sep 2025 stood at 433.7% (up 45147.0% YoY), and the FY2025 full-year result was 22503.1%, down 2157976.0% from the prior year.
- EBIT Margin rose to 246.79% in Q3 2025 per ABVC's latest filing, from 35837.44% in the prior quarter.
- Across five years, EBIT Margin topped out at 17059.12% in Q4 2021 and bottomed at 235539.83% in Q1 2024.
- Historically, EBIT Margin has averaged 21949.12% across 5 years, with a median of 1990.48% in 2021.
- The widest YoY moves for EBIT Margin: up 3517740 bps in 2024, down 23405379 bps in 2024.
- Over 5 years, EBIT Margin stood at 17059.12% in 2021, then slumped by 103 bps to 531.92% in 2022, then sank by 4345 bps to 23641.34% in 2023, then sank by 52 bps to 35837.44% in 2024, then jumped by 99 bps to 246.79% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 246.79%, 35837.44%, and 77.66% for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -246.79% |
| Dec 31, 2024 | -35,837.44% |
| Sep 30, 2024 | -77.66% |
| Jun 30, 2024 | -734.24% |
| Mar 31, 2024 | -235,539.83% |
| Dec 31, 2023 | -23,641.34% |
| Sep 30, 2023 | -13,566.31% |
| Jun 30, 2023 | -35,911.64% |
| Mar 31, 2023 | -1,486.05% |
| Dec 31, 2022 | -531.92% |
| Sep 30, 2022 | -8,790.94% |
| Jun 30, 2022 | -654.24% |
| Mar 31, 2022 | -24,235.08% |
| Dec 31, 2021 | 17,059.12% |
| Sep 30, 2021 | -1,990.48% |
| Jun 30, 2021 | -6,474.08% |
| Mar 31, 2021 | -476.06% |
| Dec 31, 2020 | -7,799.30% |
| Sep 30, 2020 | -1,116.17% |
| Jun 30, 2020 | -527.13% |